Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel disease

被引：0
|
作者：
Papamichael, K. [1 ]
Cheifetz, A. S. [1 ]
机构：
[1] Harvard Med Sch, Div Gastroenterol, Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, Boston, MA 02115 USA
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2018年 / 47卷 / 03期
关键词：
ULCERATIVE-COLITIS; CROHNS-DISEASE; INFLIXIMAB;
D O I：
10.1111/apt.14461
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：436 / 437
页数：2
相关论文
共 50 条
  • [41] Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease
    Papamichael, Konstantinos
    Juncadella, Anna
    Wong, Danny
    Rakowsky, Shana
    Sattler, Lindsey A.
    Campbell, James P.
    Vaughn, Byron P.
    Cheifetz, Adam S.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 (08): : 976 - 981
  • [42] Real World Experience in Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Lack of Anti-Drug Antibodies to Vedolizumab and Ustekinumab Compared to Anti-TNF Agents in IBD
    Glassner, Kerri L.
    Oglat, Ayah
    Abraham, Bincy
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S342 - S343
  • [43] Advantages of a fully automated chemiluminescent method for therapeutic drug monitoring (TDM) of anti-TNFα in patients with Inflammatory Bowel Diseases
    Cifu, A.
    Marino, M.
    Sablich, R.
    Carletti, M.
    Blasone, N.
    Milloch, S.
    Curcio, F.
    Fabris, M.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I289 - I289
  • [44] Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study
    Casanova, M. J.
    Chaparro, M.
    Garcia-Sanchez, V.
    Nantes, O.
    Leo, E.
    Rojas-Feria, M.
    Jauregui-Amezaga, A.
    Garcia-Lopez, S.
    Huguet, J. M.
    Arguelles-Arias, F.
    Aicart, M.
    Marin-Jimenez, I.
    Gomez-Garcia, M.
    Munoz, F.
    Esteve, M.
    Bujanda, L.
    Cortes, X.
    Tosca, J.
    Pineda, J. R.
    Manosa, M.
    Llao, J.
    Guardiola, J.
    Perez-Martinez, I.
    Munoz, C.
    Gonzalez-Lama, Y.
    Hinojosa, J.
    Vazquez, J. M.
    Martinez-Montiel, M. P.
    Rodriguez, G. E.
    Pajares, R.
    Garcia-Sepulcre, M. F.
    Hernandez-Martinez, A.
    Perez-Calle, J. L.
    Beltran, B.
    Busquets, D.
    Ramos, L.
    Bermejo, F.
    Barrio, J.
    Barreiro-de Acosta, M.
    Roncedo, O.
    Calvet, X.
    Hervias, D.
    Gomollon, F.
    Dominguez-Antonaya, M.
    Alcain, G.
    Sicilia, B.
    Duenas, C.
    Gutierrez, A.
    Lorente-Poyatos, R.
    Dominguez, M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (01): : 120 - 131
  • [45] OUTCOMES FOLLOWING THE INTRODUCTION OF WEEK 12 ANTI-TNF DRUG AND ANTIBODY TESTING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Boal, A.
    Squires, S. I.
    Naismith, G. D.
    GUT, 2017, 66 : A252 - A253
  • [46] OUTCOMES FOLLOWING THE INTRODUCTION OF ANTI-TNF DRUG AND ANTIBODY TESTING TO A BIOLOGICS CLINIC FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Boal, A.
    Squires, S. I.
    Naismith, G. D.
    GUT, 2017, 66 : A257 - A257
  • [47] LONG TERM OUTCOMES AFTER TRANSITION TO ADULT SERVICES IN PAEDIATRIC-ONSET INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH ANTI-TNF
    Pollington, C.
    Cameron, F. L.
    Kennedy, N. A.
    Arnott, I.
    Satsangi, J.
    Wilson, D. C.
    GUT, 2015, 64 : A97 - A98
  • [48] Influence of HLA DQA1*05 genotype in patients with inflammatory bowel disease and Anti-TNF treatment with proactive therapeutic drug monitoring
    Fuentes-Valenzuela, E.
    Garcia-Alonso, F. J.
    Maroto-Martin, C.
    Juan-Casamayor, L.
    Garrote Adrados, J. A.
    Almendros Munoz, R.
    de Prado, A.
    Marinero, M. A.
    Calleja Carbajosa, R.
    Vara Castrodeza, A.
    Barrio, J.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I369 - I370
  • [49] A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy
    Yao, Jiaqi
    Jiang, Xinchan
    You, Joyce H. S.
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (02) : 275 - 282
  • [50] VALIDATED NOVEL GENETIC RISK VARIANTS CAN PREDICT ANTI-TNF AGENT RESPONSE IN INFLAMMATORY BOWEL DISEASE PATIENTS
    Wang, Ming-Hsi
    Friton, Jessica
    Raffals, Laura H.
    Leighton, Jonathan A.
    Pasha, Shabana F.
    Picco, Michael F.
    Newberry, Rodney D.
    Faubion, William
    GASTROENTEROLOGY, 2018, 154 (06) : S125 - S125
12345